About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
  • Bromodomain and Extra-Terminal Motif (BET) Proteins

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Gene expression is controlled through access to DNA, which is mediated by epigenetic modifications to histones.1,2 Bromodomain and extra-terminal motif (BET) proteins are epigenetic “readers” that bind to acetylated lysine residues on histone tails.3,4 BET proteins regulate initiation and continuation of transcription of key cell cycle control genes by recruiting and interacting with transcription factors and RNA polymerase II.5-7 Additionally, BET proteins can “bookmark” genes by remaining bound to chromatin during mitosis, thereby speeding reinitiation of transcription.5 Superenhancers, which are noncoding regions of DNA critical to oncogene transcription and maintenance of cancer cell identity, are observed to have high densities of BET binding.8

    Preclinical studies suggest that inhibition of BET may result in the downregulation of key cell cycle regulatory genes, cell cycle arrest, and apoptosis of tumor cells.4,9

    Celgene is investigating BET inhibitors, including CC-90010 and FT-1101, for the treatment of solid tumors and hematologic malignancies.

    View Related Molecules

    References

    1. Bannister A, et al. Cell Research. 2011;21:381-395. PMID: 21321607
    2. Ververis K, et al. Biologics. 2013;7:47-60. PMID: 23459471
    3. Taniguchi Y. Int J Mol Sci. 2016;17:1849. PMID: 27827996
    4. Doroshow DB, et al. Ann Oncol. 2017;28:1776-1787. PMID: 28838216
    5. Devaiah BN, et al. Transcription. 2013;4:13-17. PMID: 23131666
    6. Yang Z, et al. Mol Cell Biol. 2008;28:967-976. PMID: 18039861
    7. Mochizuki K, et al. J Biol Chem. 2008;83:9040-9048. PMID: 18223296
    8. Sengupta S, et al. Trends Cancer. 2017;3:269-281. PMID: 28718439
    9. Dawson MA, et al. Nature. 2011;478:529-533. PMID: 21964340
    10. Denis GV, et al. Cell Growth Differ. 200;11:417-424. PMID: 10965846
    11. Denis GV, et al. J Proteome Res. 2006;5:502. PMID: 16512664
    12. Chapuy B, et al. Cancer Cell. 2013;24:777-790. PMID: 24332044
    13. Filippakopoulos P, et al. Nature. 2010;468:1067-1073. PMID: 20871596